logo-loader

C4X Discovery acquires new technology

Published: 17:01 12 Jul 2016 AEST

microscope
The company's technology that helps users see the shapes of small molecules in a new level of detail and sophistication.

C4X Discovery Holdings plc (LON:C4XD) has acquired has acquired a software system that helps identify drug candidates from a private company called MolPlex, which is currently in administration.

It said it paid a “non-material amount” for the platform, which complements its Conformetrix technology that helps users see the shapes of small molecules in a new level of detail and sophistication.

This in turn means scientists are able to develop drugs that have the desired and potent impact on the illness or disease.

MolPlex will enable C4X to not only generate the chemical starting point for drug programmes in rapid time, but it can also predict whether the resulting molecules have “druggable qualities”.

Being able to carry out this sort of analysis reduces the cost, time and attrition associated with early development and increases the likelihood of eventual clinical success.

The MolPlex suite of technologies were originally developed at Newcastle University.

“We are rapidly building an internal pipeline of exciting therapeutic programmes and moving steadily towards realising our goal of becoming the world's most productive drug discovery and development company," said chief executive Dr Clive Dix.

C4X Discovery 'turns engine right over' with landmark Indivior deal

Clive Dix, chief executive of C4X Discovery Holdings plc (LON:C4XD), discusses with Proactive's Andrew Scott their licensing deal with FTSE 250-listed Indivior for its addiction behaviour suppressant, C4X3256. It is the first major partnership for C4X, which will receive US$10mln up front...

on 3/4/18